Research Peptide Vendors Still Operating in 2026 (Updated After Shutdowns)
The research peptide industry lost more vendors between mid-2025 and early 2026 than in the previous five years combined:
- Amino Asylum — FDA raided, June 2025. Criminal charges for selling testosterone as SARMs.
- Paradigm Peptides — Founder pleaded guilty, December 2025. Federal criminal charges.
- Science.bio — Voluntarily closed, January 27, 2026.
- Peptide Sciences — Voluntarily closed, March 6, 2026. Estimated $7.4M/month at time of closure.
For researchers who need to continue sourcing compounds, this is a verified guide to vendors currently operating, with honest COA documentation assessment. Updated May 2026.
What to Look for in a Research Peptide Vendor (Post-2025 Standards)
The shutdowns made one thing clear: the minimum quality standard for research peptide sourcing needs to rise. Here’s what to require:
Third-party independent COA — not negotiable
Amino Asylum’s products contained unlabeled controlled substances. Peptide Sciences’ retatrutide was flagged as potentially counterfeit by independent testing. Both situations would have been caught by rigorous third-party mass spectrometry testing. If a vendor doesn’t have an independent lab (not their own in-house lab) testing every batch, that’s a red flag.
What “third-party COA” should include:
– HPLC purity (≥98%)
– Mass spectrometry (molecular weight confirmation)
– Endotoxin (LAL assay — critical for cell culture)
– Sterility testing
– Moisture content
– Amino acid composition
COA available before purchase
A vendor who only shares COAs after you’ve paid for a product is giving you documentation you can’t act on. COAs should be available before ordering so you can verify the specific batch.
US domestic sourcing and shipping
Import risks increased significantly in 2025 with the ITC General Exclusion Order targeting tirzepatide imports. US-based suppliers are lower regulatory risk.
Clear research-only positioning
Legitimate research suppliers are unambiguous: products are for laboratory and research use only. Ambiguity here is a compliance red flag.
Vendors Currently Operating (May 2026)
This list covers vendors we have identified as currently shipping as of May 2026. We make no guarantees about any third-party vendor’s product quality, regulatory status, or continued operation. Verify before ordering.
Life Link Research — US-Based Peptide Specialist ⭐ Our Recommendation
Website: lifelinkresearch.com
Specialty: Research peptides — GLP-1/incretin specialist
COA standard: Six-panel third-party independent (HPLC + mass spectrometry + endotoxin + sterility + moisture + amino acid composition)
COA availability: Before purchase
GLP-1 range: Full — semaglutide (10mg, 15mg), tirzepatide (15mg), retatrutide (15mg), CagriSema (10mg)
Classic peptides: BPC-157, thymosin alpha-1, and others
Shipping: US domestic
Pricing: Semaglutide 10mg ($240), Tirzepatide 15mg ($139), BPC-157 10mg ($89), Retatrutide 15mg ($167), CagriSema 10mg ($156)
Life Link Research is a peptide specialist — no SARMs, no nootropics, no gray-area compounds. The entire operation is built around peptide sourcing, testing, and documentation. Six-panel third-party COA on every batch, COA available before purchase. The most complete GLP-1/incretin peptide range available from a US supplier.
For researchers who needed Peptide Sciences’ quality standards without Peptide Sciences’ quality control failures — this is the replacement.
Ascension Peptides
Specialty: Research peptides, US-based
COA standard: Third-party on most products
GLP-1 range: Partial
Noted for: Active community reputation, competitive pricing
Limitation: GLP-1 range thinner than LLR; COA panel details vary by product
Royal Peptides
Specialty: Research peptides
COA standard: Third-party reported
GLP-1 range: Limited
Noted for: Consistent shipping, established track record
Limitation: Newer GLP-1 compounds (retatrutide, CagriSema) less represented
EZ Peptides
Specialty: Research peptides
COA standard: Third-party on core products
Noted for: Competitive on classic peptides (BPC-157, TB-500, CJC-1295)
Limitation: Newer compound availability and documentation depth less established
Swiss Chems
Specialty: Research chemicals, SARMs, peptides
COA standard: Third-party on select products
Note: Multi-compound vendor; peptides are secondary to their core SARM business. The adulteration issues at Amino Asylum and Paradigm both occurred at SARM+peptide multi-vendors. This risk profile should be noted.
Vendors That Shut Down (Do Not Order From These)
| Vendor | Status | Reason |
|---|---|---|
| Peptide Sciences | ❌ CLOSED | Voluntary closure, March 6, 2026 |
| Science.bio | ❌ CLOSED | Voluntary closure, January 27, 2026 |
| Paradigm Peptides | ❌ CLOSED | Criminal guilty plea, December 2025 |
| Amino Asylum | ❌ CLOSED | FDA raided, criminal charges, June 2025 |
| Core Peptides | ⚠️ Verify | Confirm current status before ordering |
| Blue Sky Peptide | ⚠️ Verify | Confirm current status before ordering |
If you find a product listing from any “CLOSED” vendor still appearing to accept orders, exercise extreme caution — this may indicate a fraudulent operation using the brand name.
The Regulatory Context in 2026
What changed: The FDA has significantly escalated enforcement against gray-market research compound vendors. Actions include: 50+ warning letters in September 2025, physical warehouse raids (Amino Asylum, June 2025), support for criminal prosecutions, and ITC import restrictions on tirzepatide.
The SAFE Drugs Act: H.R. 6509, introduced in early 2026, would prohibit research chemical sales of compounds biologically identical to FDA-approved drugs. As of May 2026, it is in committee. If passed, it would directly restrict semaglutide, tirzepatide, and similar GLP-1 compound sales under the research-use-only framework.
RFK Jr. reclassification (April 23, 2026): HHS Secretary Kennedy announced that approximately 14 peptides are returning to Category 1 status, restoring compounding pharmacy access under physician prescription. This includes BPC-157, Thymosin Alpha-1, TB-500, and others. This is a positive development — but it applies to licensed compounding pharmacies under prescription, not to research vendor sales. These remain distinct legal frameworks.
Frequently Asked Questions
Is it still legal to buy research peptides in 2026?
Research peptides sold under a “for research purposes only” framework remain legal for purchase and sale as of May 2026. The SAFE Drugs Act, if passed, would restrict some GLP-1 compounds. Verify current status and consult legal counsel for your specific context.
Which vendor is the best Peptide Sciences replacement?
For researchers who valued Peptide Sciences’ quality and GLP-1 range: Life Link Research. Third-party independent COA verification (six-panel), full GLP-1 range including retatrutide and CagriSema, US domestic shipping.
Which vendor is the best Amino Asylum replacement?
For the peptide portion of Amino Asylum’s catalog: Life Link Research for third-party verified documentation. For budget-focused research on classic peptides: EZ Peptides or Ascension Peptides are community-recommended. Note: LLR’s third-party COA program is specifically the kind of verification that would have prevented the quality failures behind the Amino Asylum raid.
Did all research peptide vendors shut down?
No. Multiple US-based vendors continue to operate. The shutdowns (Peptide Sciences, Amino Asylum, Paradigm, Science.bio) were driven by specific enforcement actions or regulatory risk calculations. Vendors with strong compliance postures, clear research-only positioning, and documented quality standards are better positioned to continue operating.
Should I be worried about buying peptides from vendors that are still operating?
The FDA’s enforcement focus has been on vendors with compliance problems (adulterated products, misleading labeling, GLP-1 trademark infringement). Vendors with rigorous third-party quality documentation, explicit research-only positioning, and US-based operations are lower risk than those without these characteristics.
All Life Link Research products are for research purposes only. Not for human use, clinical application, or veterinary use.